Provided by Tiger Fintech (Singapore) Pte. Ltd.

Replimune Group Inc.

7.03
-0.5200-6.89%
Pre-market: 6.87-0.1600-2.28%07:41 EDT
Volume:19.69M
Turnover:139.37M
Market Cap:546.98M
PE:-2.29
High:7.62
Open:6.93
Low:6.67
Close:7.55
Loading ...

Company Profile

Company Name:
Replimune Group Inc.
Exchange:
NASDAQ
Establishment Date:
2015
Employees:
479
Office Location:
500 Unicorn Park Drive,Suite 303,Woburn,Massachusetts,United States
Zip Code:
01801
Fax:
- -
Introduction:
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Directors

Name
Position
Philip Astley Sparke
Executive Chairman
Sushil Patel
Chief Executive Officer and Director
Dieter Weinand
Lead Independent Director
Christy Oliger
Director
Joseph Slattery
Director
Kapil Dhingra
Director
Madhavan Balachandran
Director
Michael Goller
Director
Paolo Pucci
Director
Veleka Peeples Dyer
Director

Shareholders

Name
Position
Sushil Patel
Chief Executive Officer and Director
Emily Hill
Chief Financial Officer
Christopher Sarchi
Chief Commercial Officer
Konstantinos Xynos
Chief Medical Officer
Philip Astley Sparke
Executive Chairman